benzodiazepines (BZDs) are a widely prescribed class of sedative-hypnotics compounds for the treatment of a broad range of conditions as anxiety and obsessive-compulsive disorders, phobias, sleep related problems associated with insomnia and for the management of alcohol and GHB withdrawal. Zolpidem, zopiclone and zaleplon, commonly known as Z-drugs are non-benzodiazepine hypnotic drug with pharmacology similar to BDZs. Despite their usefulness, BDZs and Z-drugs present a potential for abuse and dependence. Moreover, the non-medical use of BDZs is a well-known phenomenon and represents an increasingly widespread public health problem since is associated with an elevated risk of serious health consequences or fatal overdose, especially among specific group of users. The spectrum of BDZs and Z-drugs misuse is extended by new synthetic BDZs, which may pose high risks to users, since the majority have never undergone clinical trials or tests and consequently their pharmacology and toxicology is largely unknown.

BDZs, designer BDZs, and Z-drugs: pharmacology and misuse insights / Zaami, Simona; Graziano, Silvia; Tittarelli, Roberta; Beck, Renata; Marinelli, Enrico. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - 28:15(2022), pp. 1221-1229. [10.2174/1381612827666210917145636]

BDZs, designer BDZs, and Z-drugs: pharmacology and misuse insights

Zaami, Simona
Primo
;
Graziano, Silvia
Secondo
;
Tittarelli, Roberta;Marinelli, Enrico
Ultimo
2022

Abstract

benzodiazepines (BZDs) are a widely prescribed class of sedative-hypnotics compounds for the treatment of a broad range of conditions as anxiety and obsessive-compulsive disorders, phobias, sleep related problems associated with insomnia and for the management of alcohol and GHB withdrawal. Zolpidem, zopiclone and zaleplon, commonly known as Z-drugs are non-benzodiazepine hypnotic drug with pharmacology similar to BDZs. Despite their usefulness, BDZs and Z-drugs present a potential for abuse and dependence. Moreover, the non-medical use of BDZs is a well-known phenomenon and represents an increasingly widespread public health problem since is associated with an elevated risk of serious health consequences or fatal overdose, especially among specific group of users. The spectrum of BDZs and Z-drugs misuse is extended by new synthetic BDZs, which may pose high risks to users, since the majority have never undergone clinical trials or tests and consequently their pharmacology and toxicology is largely unknown.
2022
BDZs; Z-drugs; abuse; diversion; misuse; new BDZs; pharmacology
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
BDZs, designer BDZs, and Z-drugs: pharmacology and misuse insights / Zaami, Simona; Graziano, Silvia; Tittarelli, Roberta; Beck, Renata; Marinelli, Enrico. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - 28:15(2022), pp. 1221-1229. [10.2174/1381612827666210917145636]
File allegati a questo prodotto
File Dimensione Formato  
Zaami_BDZs_2021.pdf

Open Access dal 23/11/2022

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 385.83 kB
Formato Adobe PDF
385.83 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1577247
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact